Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
TARO's Cash-to-Debt is ranked higher than
98% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. TARO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TARO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.62 Max: No Debt
Current: No Debt
Equity-to-Asset 0.91
TARO's Equity-to-Asset is ranked higher than
93% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TARO: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
TARO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17  Med: 0.53 Max: 0.91
Current: 0.91
0.17
0.91
Interest Coverage 3434.87
TARO's Interest Coverage is ranked higher than
61% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 106.84 vs. TARO: 3434.87 )
Ranked among companies with meaningful Interest Coverage only.
TARO' s Interest Coverage Range Over the Past 10 Years
Min: 2.59  Med: 207.4 Max: 3930.92
Current: 3434.87
2.59
3930.92
Piotroski F-Score: 6
Altman Z-Score: 14.21
Beneish M-Score: -3.01
WACC vs ROIC
2.93%
24.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 55.76
TARO's Operating Margin % is ranked higher than
99% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. TARO: 55.76 )
Ranked among companies with meaningful Operating Margin % only.
TARO' s Operating Margin % Range Over the Past 10 Years
Min: 13.31  Med: 44.73 Max: 64.63
Current: 55.76
13.31
64.63
Net Margin % 49.69
TARO's Net Margin % is ranked higher than
98% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. TARO: 49.69 )
Ranked among companies with meaningful Net Margin % only.
TARO' s Net Margin % Range Over the Past 10 Years
Min: 9.28  Med: 37.91 Max: 56.9
Current: 49.69
9.28
56.9
ROE % 19.99
TARO's ROE % is ranked higher than
84% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. TARO: 19.99 )
Ranked among companies with meaningful ROE % only.
TARO' s ROE % Range Over the Past 10 Years
Min: 19.01  Med: 35.23 Max: 49.88
Current: 19.99
19.01
49.88
ROA % 17.88
TARO's ROA % is ranked higher than
93% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. TARO: 17.88 )
Ranked among companies with meaningful ROA % only.
TARO' s ROA % Range Over the Past 10 Years
Min: 6.38  Med: 24.38 Max: 32.05
Current: 17.88
6.38
32.05
ROC (Joel Greenblatt) % 40.51
TARO's ROC (Joel Greenblatt) % is ranked higher than
82% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. TARO: 40.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TARO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.67  Med: 52.35 Max: 105.96
Current: 40.51
17.67
105.96
3-Year Revenue Growth Rate 7.50
TARO's 3-Year Revenue Growth Rate is ranked higher than
58% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TARO: 7.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TARO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.8  Med: 13.1 Max: 34.7
Current: 7.5
-6.8
34.7
3-Year EBITDA Growth Rate 10.10
TARO's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. TARO: 10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TARO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24.5  Med: 27.8 Max: 63.7
Current: 10.1
-24.5
63.7
3-Year EPS without NRI Growth Rate 10.70
TARO's 3-Year EPS without NRI Growth Rate is ranked higher than
56% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. TARO: 10.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TARO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 38.4 Max: 119
Current: 10.7
0
119
GuruFocus has detected 3 Warning Signs with Taro Pharmaceutical Industries Ltd TARO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TARO's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TARO Guru Trades in Q3 2016

Paul Tudor Jones 7,636 sh (+186.74%)
David Dreman 414 sh (+61.09%)
Jim Simons 629,900 sh (+1.45%)
HOTCHKIS & WILEY Sold Out
» More
Q4 2016

TARO Guru Trades in Q4 2016

Paul Tudor Jones 14,160 sh (+85.44%)
Jim Simons 547,600 sh (-13.07%)
David Dreman 36 sh (-91.30%)
» More
Q1 2017

TARO Guru Trades in Q1 2017

Paul Tudor Jones 14,789 sh (+4.44%)
David Dreman Sold Out
Jim Simons 306,200 sh (-44.08%)
» More
Q2 2017

TARO Guru Trades in Q2 2017

David Dreman 36 sh (New)
Paul Tudor Jones 13,415 sh (-9.29%)
Jim Simons 270,766 sh (-11.57%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Dreman 2017-06-30 New Buy$103.88 - $118.28 $ 108.00-4%36
David Dreman 2017-03-31 Sold Out $100 - $123.39 $ 108.00-2%0
David Dreman 2016-12-31 Reduce -91.30%0.03%$93.68 - $111 $ 108.003%36
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:SHSE:600566, TSE:4516, HKSE:00867, BUD:RICHTER, SZSE:002001, SZSE:000999, NAS:AKRX, TSX:VRX, TSE:4530, NYSE:CTLT, NYSE:PTHN, SZSE:300142, NSE:DIVISLAB, SZSE:000623, NAS:OPK, SZSE:002773, SZSE:000513, LSE:HIK, TSE:4506, SHSE:600521 » details
Traded in other countries:TAL.Germany,
Headquarter Location:Israel
Taro Pharmaceutical Industries Ltd is a science-based pharmaceutical company. It develops, manufacture and market Rx and OTC (over-the-counter) pharmaceutical products primarily in the United States, Canada and Israel.

Taro Pharmaceutical Industries Ltd produces, researches, develops and markets pharmaceutical products. Its primary focus includes semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets. It is engaged in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. It develops, manufactures and markets Rx and OTC pharmaceutical products primarily in the United States, Canada and Israel.

Top Ranked Articles about Taro Pharmaceutical Industries Ltd

Gurus' Stocks With Low P/E Ratios Some of the stocks have wide margins of safety
Gurus are buying stocks that are trading with low price-earnings (P/E) ratios. Some are greatly undervalued, according to the DCF calculator. Read more...

Ratios

vs
industry
vs
history
PE Ratio 11.02
TARO's PE Ratio is ranked higher than
88% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.41 vs. TARO: 11.02 )
Ranked among companies with meaningful PE Ratio only.
TARO' s PE Ratio Range Over the Past 10 Years
Min: 3.13  Med: 10.3 Max: 20.41
Current: 11.02
3.13
20.41
PE Ratio without NRI 11.02
TARO's PE Ratio without NRI is ranked higher than
89% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.56 vs. TARO: 11.02 )
Ranked among companies with meaningful PE Ratio without NRI only.
TARO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.84  Med: 10.32 Max: 20.41
Current: 11.02
2.84
20.41
Price-to-Owner-Earnings 9.75
TARO's Price-to-Owner-Earnings is ranked higher than
88% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.43 vs. TARO: 9.75 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TARO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.5  Med: 10.25 Max: 24.34
Current: 9.75
3.5
24.34
PB Ratio 2.07
TARO's PB Ratio is ranked higher than
62% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. TARO: 2.07 )
Ranked among companies with meaningful PB Ratio only.
TARO' s PB Ratio Range Over the Past 10 Years
Min: 1.18  Med: 2.55 Max: 6.4
Current: 2.07
1.18
6.4
PS Ratio 5.42
TARO's PS Ratio is ranked lower than
70% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. TARO: 5.42 )
Ranked among companies with meaningful PS Ratio only.
TARO' s PS Ratio Range Over the Past 10 Years
Min: 1  Med: 3.92 Max: 9.63
Current: 5.42
1
9.63
Price-to-Free-Cash-Flow 10.50
TARO's Price-to-Free-Cash-Flow is ranked higher than
83% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. TARO: 10.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TARO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.93  Med: 11.05 Max: 28.21
Current: 10.5
5.93
28.21
Price-to-Operating-Cash-Flow 9.69
TARO's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. TARO: 9.69 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TARO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.68  Med: 10.34 Max: 25.85
Current: 9.69
5.68
25.85
EV-to-EBIT 7.55
TARO's EV-to-EBIT is ranked higher than
90% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. TARO: 7.55 )
Ranked among companies with meaningful EV-to-EBIT only.
TARO' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.5  Med: 7.6 Max: 55.4
Current: 7.55
4.5
55.4
EV-to-EBITDA 7.32
TARO's EV-to-EBITDA is ranked higher than
85% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. TARO: 7.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
TARO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 6.9 Max: 55.4
Current: 7.32
4
55.4
EV-to-Revenue 4.61
TARO's EV-to-Revenue is ranked lower than
63% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. TARO: 4.61 )
Ranked among companies with meaningful EV-to-Revenue only.
TARO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 3.1 Max: 8.5
Current: 4.61
1.2
8.5
PEG Ratio 0.49
TARO's PEG Ratio is ranked higher than
90% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.89 vs. TARO: 0.49 )
Ranked among companies with meaningful PEG Ratio only.
TARO' s PEG Ratio Range Over the Past 10 Years
Min: 0.22  Med: 0.31 Max: 0.63
Current: 0.49
0.22
0.63
Shiller PE Ratio 17.86
TARO's Shiller PE Ratio is ranked higher than
81% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. TARO: 17.86 )
Ranked among companies with meaningful Shiller PE Ratio only.
TARO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.73  Med: 22.83 Max: 58.09
Current: 17.86
10.73
58.09
Current Ratio 9.40
TARO's Current Ratio is ranked higher than
90% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. TARO: 9.40 )
Ranked among companies with meaningful Current Ratio only.
TARO' s Current Ratio Range Over the Past 10 Years
Min: 0.51  Med: 2.36 Max: 9.53
Current: 9.4
0.51
9.53
Quick Ratio 8.70
TARO's Quick Ratio is ranked higher than
90% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. TARO: 8.70 )
Ranked among companies with meaningful Quick Ratio only.
TARO' s Quick Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1.76 Max: 8.85
Current: 8.7
0.29
8.85
Days Inventory 263.52
TARO's Days Inventory is ranked lower than
91% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. TARO: 263.52 )
Ranked among companies with meaningful Days Inventory only.
TARO' s Days Inventory Range Over the Past 10 Years
Min: 163.69  Med: 211.42 Max: 274.97
Current: 263.52
163.69
274.97
Days Sales Outstanding 84.08
TARO's Days Sales Outstanding is ranked lower than
59% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. TARO: 84.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
TARO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.21  Med: 74.43 Max: 94.08
Current: 84.08
63.21
94.08
Days Payable 371.95
TARO's Days Payable is ranked higher than
96% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. TARO: 371.95 )
Ranked among companies with meaningful Days Payable only.
TARO' s Days Payable Range Over the Past 10 Years
Min: 28.75  Med: 45.34 Max: 371.95
Current: 371.95
28.75
371.95

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.80
TARO's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. TARO: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TARO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.4  Med: -3.2 Max: 1.8
Current: 1.8
-18.4
1.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.41
TARO's Price-to-Net-Cash is ranked higher than
51% of the 234 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.00 vs. TARO: 10.41 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TARO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.83  Med: 15.26 Max: 190.55
Current: 10.41
6.83
190.55
Price-to-Net-Current-Asset-Value 2.55
TARO's Price-to-Net-Current-Asset-Value is ranked higher than
85% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. TARO: 2.55 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TARO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.48  Med: 6.17 Max: 730.33
Current: 2.55
2.48
730.33
Price-to-Tangible-Book 2.05
TARO's Price-to-Tangible-Book is ranked higher than
69% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. TARO: 2.05 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TARO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 2.42 Max: 21.79
Current: 2.05
0.89
21.79
Price-to-Intrinsic-Value-Projected-FCF 0.67
TARO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
90% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. TARO: 0.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TARO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.8 Max: 23.54
Current: 0.67
0.65
23.54
Price-to-Median-PS-Value 1.40
TARO's Price-to-Median-PS-Value is ranked lower than
76% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. TARO: 1.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TARO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.1  Med: 0.65 Max: 2.27
Current: 1.4
0.1
2.27
Price-to-Peter-Lynch-Fair-Value 0.58
TARO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
90% of the 183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. TARO: 0.58 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TARO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.71 Max: 22.71
Current: 0.58
0.13
22.71
Price-to-Graham-Number 1.00
TARO's Price-to-Graham-Number is ranked higher than
78% of the 438 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.97 vs. TARO: 1.00 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TARO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.41  Med: 1.17 Max: 11.74
Current: 1
0.41
11.74
Earnings Yield (Greenblatt) % 13.26
TARO's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. TARO: 13.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TARO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3152.2  Med: 12.8 Max: 22.4
Current: 13.26
-3152.2
22.4
Forward Rate of Return (Yacktman) % 26.07
TARO's Forward Rate of Return (Yacktman) % is ranked higher than
82% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. TARO: 26.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TARO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21.4  Med: 4 Max: 53.9
Current: 26.07
-21.4
53.9

More Statistics

Revenue (TTM) (Mil) $806.92
EPS (TTM) $ 9.83
Beta0.15
Short Percentage of Float15.34%
52-Week Range $92.28 - 124.52
Shares Outstanding (Mil)40.51

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}